bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.043851; this version posted April 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. PRP4K is a haploinsufficient tumour suppressor negatively regulated during epithelial-to- mesenchymal transition Livia E. Clarke1, Carter Van Iderstine1, Sabateeshan Mathavarajah1, Amit Bera2, Moamen Bydoun1, Allyson Cook1, Stephen M. Lewis2,3,4,5 and Graham Dellaire1,5,6* 1. Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada 2. Atlantic Cancer Research Institute, Moncton, New Brunswick, E1C 8X3, Canada 3. Department of Chemistry & Biochemistry, Université de Moncton, Moncton, New Brunswick Canada 4. Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada 5. Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada 6. Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada *Corresponding Author: Graham Dellaire, Ph.D. Departments of Pathology and Biochemistry & Molecular Biology Dalhousie University, P.O. BOX 15000 Halifax, Nova Scotia, Canada, B3H 4R2 Tel: (902)494-4730 Fax: (902)494-2519 E-mail:
[email protected] Key words: PRP4K; PRPF4B; eIF3e; epithelial-to-mesenchymal transition (EMT); partial EMT; haploinsufficient tumour suppression; YAP 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.043851; this version posted April 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.